Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|July 8, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-02-2017
- Volume 12
- Issue 8
Recro Gainesville Adds Manufacturing Capacity
Author(s)Pharmaceutical Technology Editors
Recro Gainsville expands its tableting capacity with the addition of a tablet press and film coater.
Advertisement
Recro Gainesville, LLC, wholly-owned subsidiary of Recro Pharma, Inc., announced on May 24, 2017 the expansion of its capabilities with the addition of a tablet manufacturing suite and growing its development team.
The company’s new suite includes a Fette FE 55 tablet press, which will enable the company to compress single- and bi-layer tablets at commercial speeds, and a Bohle BTC-100 film coater.
“As long-term leaders in the development of extended release technology, we pride ourselves in meeting our clients’ exact standards,” said Scott Rizzo, general manager, in a press release. “By expanding our equipment line and adding nearly a dozen more scientists to our team, we are able to offer yet more services to meet our clients’ needs.”
Recro offers formulation, reformulation, analytical method development, manufacturing and packaging, and logistics services and can take delayed release, sustained release, or combination release products from development to commercialization.
Source:
Articles in this issue
about 9 years ago
New Reactors Spur Continuous API Manufacturingabout 9 years ago
New Lab Instruments Tackle Workflow Challengesabout 9 years ago
Lonza Launches New Biomanufacturing Complexabout 9 years ago
FDA to Lead International Effort to Secure the Supply Chainabout 9 years ago
Report: Dose CMOs Stuck in Idleabout 9 years ago
Catalent Adds Early Development Offerings to OptiForm Platformabout 9 years ago
Nitto Denko Avecia Announces Manufacturing Expansionabout 9 years ago
Alcami Relocates Headquarters to Research Triangle Park, NCAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5